The management of neonatal pulmonary hypertension

2011 Archives of Disease in Childhood Fetal & Neonatal 83 citations

Abstract

Most neonates with clinically significant pulmonary hypertension (PH) will have either persistent PH of the newborn (PPHN) or bronchopulmonary dysplasia. Cyanotic congenital heart disease must be actively ruled out as part of the differential diagnosis of PPHN. The maintenance of ductal patency with prostaglandins E1 or E2 in cases of doubt is safe and potentially beneficial given their pulmonary vasorelaxant properties. Specific tools in the treatment of PPHN include modern ventilatory strategies, inhaled nitric oxide, sildenafil, prostacyclin and extracorporeal membrane oxygenation. Rarely will a cardiac lesion be primarily responsible for neonatal PH although pulmonary vein stenosis and the persistence of an arterial duct must be considered, particularly in the older preterm baby with bronchopulmonary dysplasia.

Keywords

MedicineExtracorporeal membrane oxygenationBronchopulmonary dysplasiaPulmonary hypertensionPersistent pulmonary hypertensionDuctus arteriosusSildenafilCardiologyProstacyclinInternal medicinePregnancy

Affiliated Institutions

Related Publications

Publication Info

Year
2011
Type
review
Volume
97
Issue
3
Pages
F223-F228
Citations
83
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

83
OpenAlex

Cite This

Rami Dhillon (2011). The management of neonatal pulmonary hypertension. Archives of Disease in Childhood Fetal & Neonatal , 97 (3) , F223-F228. https://doi.org/10.1136/adc.2009.180091

Identifiers

DOI
10.1136/adc.2009.180091